Compare WHG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | VTVT |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 148.7M |
| IPO Year | 2002 | 2015 |
| Metric | WHG | VTVT |
|---|---|---|
| Price | $20.34 | $34.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | 31.4K | ★ 48.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $97,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $226.00 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.70 | $14.00 |
| 52 Week High | $20.97 | $44.00 |
| Indicator | WHG | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 48.51 |
| Support Level | $15.78 | $34.02 |
| Resistance Level | $20.97 | $40.36 |
| Average True Range (ATR) | 1.17 | 2.65 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 70.76 | 31.41 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.